On March 9, 2021, Innoviva, Inc. (the
“Company”) appointed Deborah L. Birx, M.D., to its Board of Directors (the “
where she will serve as an independent director. Dr. Birx is a world renowned medical expert and leader who most
recently served as the response coordinator of the White House Coronavirus Task Force. Dr. Birx’s career
highlights also include having served as Ambassador-at-Large, when she assumed the role of the Coordinator of the United
States Government Activities to Combat HIV/AIDS and U.S. Special Representative for Global Health Diplomacy. Dr. Birx
also served as the U.S. Global AIDS Coordinator where she oversaw the President’s Emergency Plan for AIDS Relief
(PEPFAR) at the CDC and as the Director of the U.S. Militar y HIV Research Program (USMHRP) at the Walter Reed Army Institute
Dr. Birx has published over 230 manuscripts in peer-reviewed
journals, authored nearly a dozen chapters in scientific publications, as well as developed and patented vaccines. She received
her medical degree from the Hershey School of Medicine, Pennsylvania State University, and beginning in 1980 she trained in internal
medicine and basic and clinical immunology at the Walter Reed Army Medical Center and the National Institutes of Health. Dr. Birx
is board certified in internal medicine, allergy and immunology, and diagnostic and clinical laboratory immunology.
Dr. Birx served in the United States
Army from 1980 until 2008, retiring with the rank of colonel.
There is no arrangement or understanding
between Dr. Birx and any other persons, pursuant to which Dr. Birx was selected as a director.
Dr. Birx will serve as a member
of the audit committee and the nominating/corporate governance committee of the Board.
Since January 1, 2020 there have not
been, nor are there any currently proposed to be, any transactions, in which Innoviva was or is to be a participant and the amount
involved exceeds $120,000, and in which Dr. Birx had or will have a direct or indirect material interest.
Dr. Birx is not party to any material
plan, contract or arrangement.
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
Date: March 10, 2021
Chief Executive Officer
makes a similar move, sign up!
Other recent filings from the company include the following:
OrbiMed Genesis GP LLC just provided an update on activist position in Theravance - Oct. 19, 2021
James just provided an update on activist position in Theravance - Oct. 18, 2021
Major owner of Theravance just declared 0 ownership of the company. - Oct. 15, 2021
Major owner of Theravance just picked up 1,615,427 shares - Oct. 15, 2021
Theravance's See Remarks just picked up 625 shares - Oct. 14, 2021